Is Atara Biotherapeutics Inc (ATRA) a Stock to Watch After Gaining 107.69% This Week?

Atara Biotherapeutics Inc (ATRA) stock has risen 107.69% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Atara Biotherapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ATRA!

See Full ATRA Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With ATRA Stock Today?

Atara Biotherapeutics Inc (ATRA) stock is trading at $0.54 as of 12:53 PM on Monday, Nov 20, a gain of $0.03, or 5.69% from the previous closing price of $0.51. The stock has traded between $0.51 and $0.58 so far today. Volume today is 5,089,824 compared to average volume of 6,148,199. To see InvestorsObserver's Sentiment Score for Atara Biotherapeutics Inc click here.

More About Atara Biotherapeutics Inc

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and CAR T Programs. Click Here to get the full Stock Report for Atara Biotherapeutics Inc stock.